Treatment Updates in Acute Myeloid Leukemia

Presented by:
Alexander E. Perl
Search for other papers by Alexander E. Perl in
Current site
Google Scholar
PubMed
Close
 MD, MS
Restricted access

The NCCN Guidelines for the management of acute myeloid leukemia (AML) have, for the most part, remained unchanged from 2020, with some shifts in emphasis, fine-tuning, and several important updates in the 2021 version. The guidelines now emphasize physiologic age rather than chronologic age, and recommend that fit patients should receive intensive chemotherapy. Actionable genetics are being used to guide selection of therapy. Minimal residual disease assessment after induction therapy is now incorporated in the guidelines. New therapeutic options include oral azacitidine and combination venetoclax + azacitidine, and preliminary evidence suggests that IDH inhibitors will come to the fore in the treatment of AML.

Disclosures: Dr. Perl has disclosed receiving honoraria from and serving as a scientific advisor for AbbVie, Inc., Actinium Pharmaceuticals, Astellas Pharma US, Inc., Celgene Corporation, Daiichi-Sankyo Co., Genentech, Inc., Loxo Oncology, Inc., Sumitomo Dainippon, and Syndax; receiving grant/research support from AbbVie, Inc., Astellas Pharma US, Inc., Daiichi-Sankyo Co., and Fujifilm Corporation; and receiving consulting fees from AbbVie, Inc., Astellas Pharma US, Inc., OncoNova, BeatAML LLC, Daiichi-Sankyo Co., and Forma Therapeutics.

Correspondence: Alexander E. Perl, MD, MS, Abramson Cancer Center at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman 12 South, Philadelphia, PA 19104. Email: alexander.perl@pennmedicine.upenn.edu
  • Collapse
  • Expand
  • 1.

    Cicconi L, Platzbecker U, Avvisati G, et al. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia 2020;34:914918.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: a meta-analysis of individual patient data from randomized controlled trials. Lancet Oncol 2014;15:986989.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Stone RM, Mandrekar S, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377:454464.

  • 4.

    Döhner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 2020;135:371380.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Voso MT, Larson RA, Jones D, et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv 2020;4:49454954.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 2020;383:25262537.

  • 7.

    Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol 2020;38:29933002.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem-cell transplantation: an open-label, multicenter, randomized phase 3 trial. Lancet Oncol 2020;21:12011212.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax for previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617629.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1265 481 21
PDF Downloads 770 71 5
EPUB Downloads 0 0 0